Alivus Life

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE03Q201024
NSEID: ALIVUS
BSEID: 543322

INR

885.95

15.35 (1.76%)

BSENSE

Dec 05

BSE+NSE Vol: 1.48 lacs

Click here to access the older version

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Acutaas Chemical

Granules India

P & G Health Ltd

Natco Pharma

Alivus Life

Blue Jet Health

Caplin Point Lab

Sanofi Consumer

Sanofi India

Concord Biotech

Rubicon Research

Why is Alivus Life Sciences Ltd ?

Poor long term growth as Net Sales has grown by an annual rate of 4.84% and Operating profit at 2.21% over the last 5 years

Flat results in Sep 25

CASH AND CASH EQUIVALENTS(HY) Lowest at Rs 19.18 cr

Underperformed the market in the last 1 year

Even though the market (BSE500) has generated returns of 2.13% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -17.87% returns

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Alivus Life for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Alivus Life

-17.87%

-0.48

37.44%

Sensex

4.85%

0.41

11.83%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

4.84%

EBIT Growth (5y)

2.21%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt is too low

Net Debt to Equity (avg)

-0.20

Sales to Capital Employed (avg)

1.10

Tax Ratio

25.67%

Dividend Payout Ratio

58.54%

Pledged Shares

Institutional Holding

12.31%

ROCE (avg)

37.18%

ROE (avg)

18.73%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.53

EV to EBIT

14.94

EV to EBITDA

13.60

EV to Capital Employed

4.15

EV to Sales

4.06

PEG Ratio

0.80

Dividend Yield

0.58%

ROCE (Latest)

27.80%

ROE (Latest)

17.59%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company

PAT(9M)

At Rs 393.44 cr has Grown at 29.11%

-1What is not working for the Company

CASH AND CASH EQUIVALENTS(HY)

Lowest at Rs 19.18 cr

Loading Valuation Snapshot...

Here's what is working for Alivus Life

Profit After Tax (PAT) - Latest six months

At Rs 251.57 cr has Grown at 21.65%

Year on Year (YoY)

MOJO Watch

Near term PAT trend is positive

PAT (Rs Cr)

Here's what is not working for Alivus Life

Cash and Cash Equivalents - Half Yearly

Lowest at Rs 19.18 cr

in the last six half yearly periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Non Operating Income - Quarterly

Highest at Rs 14.72 cr

in the last five quarters

MOJO Watch

Increased income from non business activities may not be sustainable

Non Operating Income